Group 1 - The company has established a unified financial system prior to its listing, promoting the integration of financial and business data [2] - The company is implementing vertical financial management, business planning (BP), and centralized fund management [2] - The company will continue to optimize its financial digital processes, enhancing system integration and compliance efficiency [2] Group 2 - The company aims to further improve its overall management level to efficiently match its business development [2]

Group 1 - The company focuses on its core business while continuously monitoring and exploring new technologies and markets [2] - The company aims to expand its layout in the healthcare sector [2]

Core Viewpoint - Aibo Medical emphasizes that its stock price fluctuations in the secondary market are influenced by multiple factors, including macroeconomic conditions, industry cycles, and market sentiment, while the company aims to enhance its value through various means and effectively return value to shareholders [2] Group 1: Company Strategy - The company has established a good reputation among doctors and patients for its multiple artificial lens products, which are backed by outstanding technological advantages [2] - Aibo Medical plans to actively seize market opportunities to continuously increase its market share [2]

Core Viewpoint - Aibo Medical has a strong market share and leading position in the ophthalmic surgery and myopia prevention market in China, with a rapidly growing vision care business and plans to expand into high-comfort, functional consumer products [1] Group 1 - The company has a high market share in the ophthalmic surgery and myopia prevention market in China [1] - The vision care business is currently in a rapid growth phase [1] - The company is accelerating its expansion into high-comfort and functional consumer product markets [1]

Core Viewpoint - The company leverages five proprietary technology platforms to develop innovative products that are both domestically pioneering and internationally leading [1] Group 1: Company Strategy - The company adheres to a dual-driven strategy of "medical + consumer" and internationalization, aiming for steady and sustainable high-quality development [1]

格隆汇2月11日丨爱博医疗(688050.SH)在投资者互动平台表示，公司暂无光模块相关布局与研究。 ...

Group 1 - The company, Aibo Medical (688050.SH), holds a significant market share and leading position in the ophthalmic surgery and myopia prevention market in China [1] - The vision care business is currently experiencing rapid growth and is accelerating its expansion into high comfort and functional consumer product markets [1] - The company expresses strong confidence in its future development and will continue to actively promote market expansion [1]

Group 1 - The company has a high market share and leading position in the ophthalmic surgery and myopia prevention market in China [1] - The vision care business is experiencing rapid growth and is accelerating its expansion into high comfort and functional consumer product markets [1] - The company is confident about its future development and will continue to actively promote market expansion [1]

格隆汇2月11日丨爱博医疗(688050.SH)在投资者互动平台表示，公司暂无光模块相关布局与研究。 ...

来源：扬州国金集团 每日｜荐读 热文： 谁押中了沐曦股份？ 荐读： 2025募资市场年度观察：一年聊过239家LP的真实感受 荐读： 2025年IPO退出盘点：哪些GP赚钱了？ 热文： 投资人"忙疯了" 2026年1月23日，爱博弘盛（扬州）股权投资基金合伙企业（有限合伙）完成工商登记，标志着 扬州市首支CVC生物医药产业子基金顺利落地。该基金由国信弘盛私募基金管理有限公司担任基 金管理人及执行事务合伙人，联合爱博医疗（688050.SH）、扬州市生物医药产业投资基金、广 陵区共同出资设立， 总认缴规模5亿元。 据悉，该基金未来将联合产业龙头与地方国资，以"产业+资本+券商资源"为核心模式，聚焦生物 医药赛道，开展专业化投资布局。 ...